Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

Peer Review reports

Original Submission
23 Dec 2013	Submitted	Original manuscript
23 Dec 2013	Author responded	Author comments - Luis Ruilope
Resubmission - Version 2
23 Dec 2013	Submitted	Manuscript version 2
8 Jan 2014	Author responded	Author comments - Luis Ruilope
Resubmission - Version 3
8 Jan 2014	Submitted	Manuscript version 3
11 Feb 2014	Reviewed	Reviewer Report - Fernando Gerchman
15 Mar 2014	Reviewed	Reviewer Report - Anna Solini
12 May 2014	Author responded	Author comments - Luis Ruilope
Resubmission - Version 4
12 May 2014	Submitted	Manuscript version 4
25 Jun 2014	Author responded	Author comments - Luis Ruilope
Resubmission - Version 5
25 Jun 2014	Submitted	Manuscript version 5
11 Aug 2014	Author responded	Author comments - Luis Ruilope
Resubmission - Version 6
11 Aug 2014	Submitted	Manuscript version 6
11 Sep 2014	Author responded	Author comments - Luis Ruilope
Resubmission - Version 7
11 Sep 2014	Submitted	Manuscript version 7
Publishing
22 Sep 2014	Editorially accepted
18 Nov 2014	Article published	10.1186/1471-2369-15-180

Back to article page